Neuraxpharm and Pharmathen Collaborate on Injectable Therapies

Strategic Alliance between Neuraxpharm and Pharmathen

Neuraxpharm Group (Neuraxpharm) is excited to announce a significant strategic partnership with Pharmathen, an esteemed player in the pharmaceutical industry known for its expertise in long-acting injectable (LAI) therapies. This collaboration aims to create innovative long-acting injectable therapies targeting central nervous system (CNS) disorders, offering patients better treatment options.

Enhancing Patient Experience in CNS Treatment

The new therapies developed through this partnership promise to provide greater flexibility and choice for patients dealing with challenging CNS conditions. By transitioning from traditional short-acting dosage forms to long-acting injectables, both companies aim to enhance patient compliance and improve overall treatment convenience.

Exclusive Rights and Market Strategy

As per the agreement, Neuraxpharm will hold exclusive rights to commercialize these new therapies across Europe and in other regions where they maintain a direct presence. Pharmathen will focus on North America and additional markets not directly covered by Neuraxpharm. This strategic division of territories allows both companies to leverage their strengths in different markets effectively.

Pharmathen's Innovative Technologies

Pharmathen’s Long-Acting Therapeutic Technologies (LATT) program utilizes advanced proprietary technologies to enhance existing treatment options. This program aims to replace traditional tablets or injectable therapies with long-lasting formulations that can lead to improved symptom control over an extended period.

Neuraxpharm's Expertise in CNS Products

Neuraxpharm brings more than three decades of experience in developing and commercializing CNS products across Europe. They possess robust commercialization expertise and a solid track record in the pharmaceutical market, having established a presence in over 20 European countries along with a global network of distributors.

Statements from Leadership

Dr. Jörg-Thomas Dierks, the CEO of Neuraxpharm, emphasized the importance of this partnership. He stated, "This alliance showcases our commitment to delivering innovative solutions that cater to the needs of CNS patients across Europe and beyond. By introducing these well-established therapies in a new format, we aim to empower patients with better control over their treatment plans."

Dimitris Kadis, CEO of Pharmathen, added, "Our mission revolves around improving the lives of patients through innovation. Collaborating with Neuraxpharm marks a pivotal step in this journey, as it enhances access to our advanced therapeutic technologies, ultimately benefiting CNS patients worldwide."

About the Neuraxpharm Group

Neuraxpharm stands as a prominent European specialty pharmaceutical company focused on the CNS, which encompasses both psychiatric and neurological disorders. With a comprehensive understanding built over 35 years, Neuraxpharm is dedicated to enriching patient care through continual innovation.

The company has a substantial workforce of around 1,000 employees and delivers CNS products across Europe, as well as in Latin America and the Middle East. Backed by funds advised by Permira, Neuraxpharm aims to expand its portfolio through innovative products and strategic partnerships.

About Pharmathen

Founded in 1969, Pharmathen has become a pillar in the pharmaceutical landscape, known for developing cutting-edge formulations and innovative drug delivery systems. With robust R&D capabilities, their extensive portfolio includes over 90 commercial products sold in more than 90 countries, enhancing accessibility for patients globally.

Their facilities in Greece are certified by both the FDA and EU authorities, allowing them to maintain high manufacturing standards. This broad reach enables Pharmathen to support patients and prescribers effectively through their product offerings.

Frequently Asked Questions

What is the main focus of the Neuraxpharm and Pharmathen partnership?

The partnership primarily focuses on developing long-acting injectable therapies for treating central nervous system disorders.

What innovations are expected from the collaboration?

Expect enhancements in patient treatment options through long-acting injectables that improve compliance and provide better symptom control.

Which markets will Neuraxpharm and Pharmathen serve?

Neuraxpharm will address the European market while Pharmathen will focus on North America and other regions.

What is Pharmathen's expertise in the pharmaceutical industry?

Pharmathen is renowned for its long-acting therapeutic technologies, often replacing traditional medication forms with innovative long-lasting treatments.

How many countries does Neuraxpharm operate in?

Neuraxpharm operates in over 20 European countries and maintains a presence in Latin America and the Middle East.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.